Recombinant Technologies
Early Stage
Revolutionary Alzheimer's Treatment
Overview
Raised: $98,143
Total Commitments ($USD)
Platform
StartEngine
Start Date
07/14/2021
Close Date
02/11/2022
Min. Goal
$10,000
Max. Goal
$1,070,000
Min. Investment
$200
Security Type
Equity - Common
Series
Pre-Seed
SEC Filing Type
RegCF
Price Per Share
$1.00
Pre-Money Valuation
$35,000,000
Rolling Commitments ($USD)
Status
Funded
Reporting Date
02/27/2022
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$465
# of Investors
191
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2021
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
Recombinant Technologies, with a pre-money valuation of $35 million, is raising crowdfunding on StartEngine. The company is developing a revolutionary treatment for Alzheimer’s Disease. It is designing a process of injecting a molecule into the patients to reduce the plaque buildup that causes dementia. Dr. Pazhani Sundaram founded Recombinant Technologies in May 2021. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,070,000, and the proceeds will be used to complete the studies to get the FDA approval of the device. Recombinant Technologies’ patented technology was developed with $4.5 million in grants and has been shown to improve memory in mice.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$492,479 |
$562,257 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-118,775 |
$-182,716 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$123 |
$205 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$28,023 |
$18,605 |
|
Short-Term Debt |
$140,219 |
$149,919 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$140,219 |
$149,919 |
Financials as of: 07/14/2021
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.